Aktie A2P85Z NURIX THERAPEUTICS, INC.
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren

Andere Sprachen Nurix Therapeutics, Inc.

Aktien

A2P85Z

US67080M1036

NRIX

Markt geschlossen - Nasdaq
Andere Börsenplätze
 22:00:00 27.06.2024 		% 5 Tage % 1. Jan.
20,74 USD +1,37 % Intraday Chart für Nurix Therapeutics, Inc. -1,10 % +100,97 %
20.06. Nurix Therapeutics Insider verkaufte Aktien im Wert von $400.216, laut einer aktuellen SEC Einreichung MT
18.06. NURIX THERAPEUTICS, INC. : HC Wainwright bleibt bei seiner Kaufempfehlung ZM

Andere Sprachen

Suchen
Ergebnisse ansehen
Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!
100% kostenlose Registrierung
Nurix Therapeutics Insider Sold Shares Worth $400,216, According to a Recent SEC Filing
Sector Update: Health Care Stocks Decline Premarket Monday
Investors Look for Fresh Impetus Ahead of Holiday Break, Stifling US Equity Futures Pre-Bell
Sector Update: Health Care
Exchange-Traded Funds, Equity Futures Mixed Pre-Bell Monday Ahead of More Economic Data
Top Premarket Gainers
Nurix Therapeutics Says Patients Respond Well to Potential Non-Hodgkin Lymphoma Treatment in Phase 1 Trial
Nurix Therapeutics Presents Positive Results from Ongoing Clinical Trial of NX-5948 in Patients with Relapsed Refractory Chronic Lymphocytic Leukemia (CLL) at the European Hematology Association Congress (EHA2024)
Nurix Therapeutics Presents Positive Results from Ongoing Clinical Trial of NX-5948 in Patients with Relapsed Refractory Chronic Lymphocytic Leukemia At the European Hematology Association Congress
Nurix Therapeutics Files Mixed Shelf Registration
Certain Restricted Stock Units of Nurix Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 11-JUN-2024.
Certain Stock Options of Nurix Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 11-JUN-2024.
Certain Pre-Funded Warrants of Nurix Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 11-JUN-2024.
Certain Common Stock of Nurix Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 11-JUN-2024.
Nurix Therapeutics to Host a Webcast and Conference Call to Discuss Data from the Ongoing Phase 1 Clinical Trial of NX-5948 Being Presented at the European Hematology Association Congress (EHA2024)
Nurix Therapeutics to Participate in the Jefferies Global Healthcare Conference
Nurix Therapeutics Appoints Paula G. O’Connor, M.D., as Chief Medical Officer and Pasit Phiasivongsa, Ph.D., as Chief Technical Officer
Nurix Therapeutics, Inc. Appoints Paula G. O?Connor as Chief Medical Officer and Pasit Phiasivongsa as Chief Technical Officer
Nurix Therapeutics Names New Board Chair
Nurix Therapeutics Announces Board Chair Transition
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. A2P85Z Aktie
  4. Nachrichten Nurix Therapeutics, Inc.
  5. Andere Sprachen